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ABSTRACT
Background. Immunotherapeutic treatment strategies
including adoptive cell transfer (ACT) for metastatic
melanoma are capable of mediating complete and durable
responses, as well as partial responses and prolonged dis-
ease stabilization. Unfortunately, many patients ultimately
develop progressive disease. The role of salvage metasta-
sectomy in managing these patients has not been evaluated.
Methods. Records of patients with metastatic melanoma
treated with ACT at a single institution between 2000 and
2014 were reviewed. Patients with an objective response
by RECIST criteria or disease stabilization of at least 6
months and who subsequently developed progressive
melanoma and were managed with metastasectomy as the
next therapeutic strategy were studied for progression-free
survival (PFS) and overall survival (OS). Five additional
clinical parameters were also reviewed for association with
outcomes.
Results. Of 115 patients treated with ACT who met our
response criteria and then developed progressive disease, 26
(23%) had surgery. There were no mortalities related to
surgical intervention. Median follow-up after surgery was 62
months. Median PFS after surgery was 11 months and five-
year OS was 57%. The development of a new site of
metastasis after ACT was associated with poor PFS and OS.
Conclusions. Surgery after immunotherapy is safe. Long
PFS and OS can be achieved by metastasectomy in selected
patients with progressive melanoma following treatment
with ACT. Clinical variables important for patient selec-
tion for metastasectomy after immunotherapy remain
largely undefined. Improvements in immunotherapeutic
treatment strategies may increase the role of surgery for
patients with advanced disease.
Recent advances in immunotherapy using adoptive cell
transfer (ACT) of autologous lymphocytes1–7 and check-
point inhibitors8–11 have dramatically altered the
therapeutic landscape for patients with advanced mela-
noma. These immune-based strategies can mediate
complete and durable responses, as well as partial responses
(PRs) and prolonged disease stabilization. Unfortunately,
many patients ultimately develop progressive melanoma
after treatment. More specifically, the complete response
(CR) rate following ACT has been reported to be 24 %,
while another 30 % of patients experienced a PR, with an
overall response rate of approximately 55 %. In this setting,
CRs are almost always durable, but approximately 70 % of
patients with only a PR subsequently developed progressive
disease.7 For these patients, metastasectomy can be con-
sidered if tumor progression is limited.12,13
This report describes our experience using metastasec-
tomy as the next treatment for a selected cohort of patients
who developed progressive melanoma after having
achieved an objective response or disease stabilization for
at least 6 months following ACT. We primarily studied
progression-free survival (PFS) and overall survival (OS)
after salvage metastasectomy, and also studied five clinical
variables to test whether any were associated with out-
comes in this highly selected group of patients.
METHODS
Patient Selection Criteria and Clinical Protocols
Our intent was to investigate the impact of metastasec-
tomy for patients with advanced melanoma who had a
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clinical response to ACT given at the Surgery Branch,
National Cancer Institute (NCI). To be included in this
analysis, patients were required to have achieved an
objective PR or CR according to Response Evaluation
Criteria in Solid Tumors (RECIST) 1.0.14 We also included
patients with stable disease (SD) documented for at least 6
months (SD6) following ACT as this appears to be an
important and reproducible outcome following
immunotherapy.15 Following an initial clinical response,
all patients in this study had documented disease progres-
sion and underwent metastasectomy as the next treatment
modality. We excluded patients who underwent surgery for
research or palliation, and those who had resection of sites
of prolonged SD without overt progression. Finally,
patients with progressive brain metastases were excluded
because they almost always require an intervention. All
patients had viable melanoma confirmed in the surgical
specimen.
Adoptive Cell Transfer Protocols
Patients in this analysis had a diagnosis of metastatic
melanoma and were enrolled in one of 11 Institutional
Review Board (IRB)-approved clinical protocols transfer-
ring autologous tumor-infiltrating lymphocytes (TILs) or
peripheral blood lymphocytes genetically modified to
express a human leukocyte antigen (HLA)-appropriate T
cell receptor (GM-PBL). Patients were required to have
measurable metastatic disease and an Eastern Cooperative
Oncology Group (ECOG) score of 1 or 2. The production,
selection, and administration of these cells have previously
been described in detail and the results of these clinical
trials have been previously published.2,6 In brief, TILs (376
patients) were generated from a resected melanoma tumor
deposit cultured in high-dose interleukin (IL)-2. TILs with
sufficient growth and/or demonstrable anti-tumor reactivity
were expanded for treatment. The GM-PBL (76 patients)
was generated by retroviral transduction of autologous
peripheral blood lymphocytes with a T-cell receptor rec-
ognizing one of four different HLA-A*02 restricted
melanoma antigens (Mage-A3, Mart-1, gp-100(154), or
NY-ESO).
Prior to lymphocyte infusion, all patients received
lymphodepleting, but non-myleoablating, chemotherapy
consisting of 2 days of cyclophosphamide (60 mg/
kg/day) followed by 5 days of fludarabine (25 mg/
m2/day). A subset of TIL patients also received total
body irradiation (2 or 12 Gy fractionated over 3 days),
along with autologous CD34? stem cell support.
Approximately 4 h after cell infusion, all patients were
started on high-dose IL-2 at 720,000 IU/kg every 8 h as
tolerated.
Protocol Surveillance and Preoperative Evaluation
Patients on ACT protocols had scheduled evaluations,
which included computed axial tomography (CT) of the
chest, abdomen, and pelvis before and within 4 weeks of
ACT and then monthly for 3 months. Patients with hepatic
disease were evaluated using magnetic resonance imaging
(MRI). Other imaging modalities were added as needed to
evaluate specific disease sites. For each protocol, patients
were evaluated every 2 months with complete imaging for
the remainder of the first year. Subsequently, imaging was
obtained at 3- to 6-month intervals for up 5 years. MRI
evaluation of the brain was required prior to protocol
enrollment and subsequently obtained every 4–6 months.
Patients undergoing metastasectomy had complete preop-
erative imaging, including brain MRI. Positron emission
tomography (PET) scans were not used for tumor response
evaluations but were obtained preoperatively at the dis-
cretion of the operating surgeon. This intensive radiologic
surveillance allowed sites of disease progression to be
retrospectively classified as either a pre-existing site or a
new site of disease, relative to the start date of ACT.
Postoperative evaluations included repeat imaging and
were obtained at 3- to 4-month intervals for the first year
and then at 6-month intervals for up to 5 years. A brain
MRI was typically obtained every other visit (or every visit
for those with a history of central nervous system [CNS]
disease). Although some patients who developed progres-
sive melanoma following surgical resection underwent
repeat metastasectomy, most patients were either enrolled
in other investigational protocols or discharged from the
Surgery Branch, NCI. Consequently, the overall survival
data for these patients may have been impacted by subse-
quent therapies.
Surgical Approach
The goal of the metastasectomy was to eliminate all
sites of progressing melanoma. Importantly, metastases
that were stable or still shrinking following cell therapy
were not necessarily resected. Patients left with no evi-
dence of disease (NED) after surgery had no residual
abnormalities identified by imaging or physical examina-
tion. Patients with stable or regressing disease after surgery
were considered to have residual disease.
Statistical Analysis
We measured PFS and OS from the date of metasta-
sectomy using the Kaplan–Meier method. Patients with
planned multistage operations were counted from the date
of the first procedure. We studied five clinical variables for
an association with postoperative outcomes using the log-
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rank method. Three of these variables have been reported
to be associated with favorable outcomes in reported series
of metastasectomy for melanoma, and include resection of
solitary or multiple tumors, postoperative disease status
(NED or residual disease), and resection of visceral or non-
visceral tumors. The disease-free interval has also been
considered to be an important prognostic factor, and con-
sequently we included the interval between ACT and
metastasectomy (\12 months or[12 months) as a factor
to be analyzed. The fifth clinical variable was whether the
resected lesion was present prior to ACT (pre-existing site)
or only became apparent after ACT (new site). We inclu-
ded this variable because of the discrepancy between
RECIST and the immune-related response criteria (irRC)
for the determination of objective anti-tumor responses. A
new tumor site is considered progressive disease using
RECIST criteria but is added to the overall tumor burden
when irRC are used.14,16 Due to the exploratory nature of
this retrospective study and the small size of the study
cohort, we did not perform a Bonferroni correction. We
planned to generate a multivariate model in the event that
two or more variables reached a threshold of p B 0.1.
RESULTS
A total of 470 patients with advanced cutaneous mela-
noma were enrolled in one of the 11 ACT protocols from
2000 to 2014 (Fig. 1). Overall, 227 patients achieved an
objective response or SD for at least 6 months. Although
the responses were durable for 94 patients, 133 patients
developed progressive melanoma, 18 of whom developed
brain metastasis and required craniotomy or radiation
therapy and were subsequently excluded from this analysis.
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FIG. 1 Patient selection
process for metastasectomy
after ACT. CR complete
response, PR partial response,
SD6 stable disease documented
for at least 6 months, PD
progressive disease
TABLE 1 Demographics of the study cohort before ACT. ACT
adoptive cell transfer
Demographics before ACT
Men, women 17, 9
Median age of ACT 49
M stage at the time of ACT M1a = 4
M1b = 3
M1c = 19
Number of metastases at the time of ACT Median = 5
Average = 6
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TABLE 2 Characteristics of the study cohort















1 M1c 5 PR 29 Adrenal pre-existing NED 10c 10c n/a
2 M1c 9 PR 39 Supraclaviular LNa pre-existing NED 13c 13c n/a
3 M1c 4 PR 17 Lung pre-existing NED 26c 26c n/a
4 M1c 4 PR 12 Thyroid pre-existing NED 48c 48c n/a
5 M1c 8 PR 15 Lung pre-existing Residual 52c 52c n/a
6 M1c 13 SD 6 Livera (x2) pre-existing NED 56c 56c n/a
7 M1c 7 PR 5 Omentum pre-existing Residual 92c 92c n/a
8 M1c 6 PR 8 Liver (x2) pre-existing NED 103c 103c n/a
9 M1c 5 SD 15 Cervical LN pre-existing Residual 4 16c Metastasectomy
10 M1c 2 PR 15 Adrenal new NED 14 21c anti-PD1
11 M1b 3 PR 14 Lung pre-existing NED 23 23c Ipilimumab
12 M1a 4 PR 5 Subcutaneous (x2) new NED 2 38c Metastasectomy
13 M1a 3 PR 23 Paratracheal LN pre-existing NED 5 61c Metastasectomy, Ipilimumab
14 M1c 2 PR 10 Stomach pre-existing NED 46 62c Ipilimumab
15 M1c 2 PR 4 Livera pre-existing NED 6 82c Metastasectomy
16 M1c 10 SD 11 Lung, Liver pre-existing NED 6 136c ACT
17 M1c 4 PR 6 Popliteal LN pre-existing Residual 79 137c Metastasectomy, ACT
18 M1c 6 SD 7 Subcutaneous (x2) new Residual 2 5 WBRT
19 M1a 15 PR 10 Subcutaneous new Residual 1 12 ACT, ipilimumab
20 M1b 6 CR 10 Cervical LN new NED 4 14 Metastasectomy, Ipilimumab
21 M1a 3 PR 5 Subcutaneous (x2) pre-existing NED 4 15 Chemotherapy
22 M1c 23 PR 12 Spleen, Adrenal new NED 3 20 Ipilimumab, ACT
23 M1c 4 PR 5 Lung pre-existing Residual 3 24 Chemo
24 M1c 13 PR 15 Axillary LN pre-existing Residual 11 27 Chemo / radiation
25 M1b 4 PR 19 Lung (x2) pre-existing NED 1b 44 ACT
26 M1c 2 PR 24 Liver new NED 40 51 Ipilimumab
Before ACT After MetastasectomyMetastasectomy Variables
M stage and metastases correspond to the stage and number of metastatic lesions known before ACT. ‘Response’ indicates the response to ACT
(using RECIST); ‘Interval’ indicates the time (in months) between ACT and metastasectomy; blue shading indicates patients with ongoing PFS
and OS after metastasectomy; green shading indicates patients with ongoing OS after progressive disease; and red shading indicates patients who
expired with disease
ACT adoptive cell transfer, RECIST Response Evaluation Criteria in Solid Tumors, PFS progression-free tumor, OS overall survival, LDH lactate
dehydrogenase, PR partial response, SD stable disease, CR complete response, LN lymph node, NED no evidence of disease, N/A not applica-
ble, WBRT whole brain radiotherapy
a Indicates elevated serum LDH at the time of metastasectomy
b Indicates incomplete resection of intended progressing lesions
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FIG. 2 Kaplan–Meier curves showing progression-free survival and overall survival (OS) after metastasectomy (n = 26)
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extracranial progressive melanoma underwent metastasec-
tomy; this highly selected cohort represents the focus of
our study.
Prior to treatment by ACT, 19 of the 26 patients even-
tually undergoing metastasectomy had M1c disease
(Tables 1, 2). These 26 patients had a median number of
five metastatic lesions per patient, with a range of 2–23
lesions. There were no mortalities related to metastasec-
tomy. With a median follow-up after metastasectomy of 62
months, the median PFS was 11 months and the 5-year OS
was 57 % for all 26 patients (Fig. 2). After surgery, nine
patients (35 %) had a PFS of more than 24 months, and six
patients (23 %) had a PFS of more than 46 months.
We found 8 of the 26 patients undergoing metastasec-
tomy remained progression-free and required no additional
therapy (Table 2). For the remaining patients, subsequent
therapies are noted. Interestingly, three additional patients
have achieved prolonged survival following only repeat
metastasectomy, and two patients have survived for over
10 years following re-treatment with ACT. The remaining
three long-term survivors were later treated with check-
point inhibitors.
Clinical Factors Associated with Favorable
Progression-Free Survival
Univariate analyses revealed no significant PFS or OS
associations between non-visceral resections, solitary sites
of resection, and NED status after surgery (Table 3). An
interval between ACT and metastasectomy of[12 months
was also not associated with improved PFS or OS. We did
observe that longer PFS and OS were significantly
associated with the resection of a pre-existing site of
metastasis compared with a new site of disease (Fig. 3).
Median PFS for these patients was 46 months and
3 months, respectively (p = 0.004). The 5-year OS rates
following surgery on pre-existing lesions versus new
lesions were 73 and 0 % respectively.
DISCUSSION
Metastasectomy in highly selected patients with
advanced melanoma is widely accepted and can potentially
be curative. Data to support the resection of metastatic
melanoma for curative intent has largely been limited to
retrospective series from single institutions.17–20 Proper
patient selection has long been recognized to be critical to
achieving optimal surgical results. Clinical factors previ-
ously shown to be associated with favorable PFS and OS
include resection of solitary tumors, non-visceral tumors,
complete resection, and prolonged disease-free interval.
There are few data describing the outcomes of metasta-
sectomy after immunotherapy. One series reported that
metastasectomy did not convincingly achieve prolonged
PFS for patients with progressive melanoma who responded
to high-dose IL-2.12 Conversely, another study noted that
patients with metastatic melanoma made free of disease by
thoracic resection had a 5-year actuarial survival rate of
76 %; the majority of these patients had been treated with IL-
2, vaccine, or interferon.13 To our knowledge, the reported
experience with metastasectomy for metastatic melanoma
following checkpoint inhibition is limited to a single report.
Gyorki et al. reported a median PFS of 9.5 months after
metastasectomy in patients being treated with ipilimumab.21
TABLE 3 Clinical factors analyzed for association with PFS and OS after metastasectomy
Univariate Number of patients Median PFS (Months) Median OS (Months) Five-year OS
Interval between ACT, surgery p = 0.34 p = 0.65
\1 year 12 5 NR 60 %
[1 year 14 23 51 49 %
Number of tumors resected p = 0.31 p = 0.58
One 18 23 NR 56 %
Two 8 3.5 44 47 %
Location of tumors p = 0.17 p = 0.43
Nodal/subcutaneous 9 4 NR 53 %
Visceral (or elevated LHD) 17 40 NR 61 %
Post-op disease status p = 0.82 p = 0.29
No evidence of disease 18 14 NR 62 %
Residual disease 8 7.5 27 45 %
Type of metastasis p = 0.004 p = 0.003
Pre-existing site 19 46 NR 73 %
New site 7 3 20 0 %
PFS progression-free survival, OS overall survival, ACT adoptive cell transfer, LDH lactate dehydrogenase, NR not reported
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Five-year survival following therapy with ipilimumab
has been reported to range from 17 to 38 %, and, following
ACT, has been reported to be over 40 %.15 Response rates
to anti-PD1 antibodies are improved over ipilimumab, and
have shown efficacy in other histologies.11,22 The ability of
these immune-based strategies to mediate complete and
durable tumor regression along with prolonged disease
stabilization prompted us to evaluate our experience using
metastasectomy as the next treatment option for patients
following ACT. This series is interesting because all 26
patients had multiple lesions and widespread disease,
which made them not ideal candidates for curative surgery
before ACT.19 For example, before ACT no patient had a
solitary metastasis, and the four patients with two metas-
tases had M1c disease. All remaining patients had three or
more metastatic lesions, with a median of five per patient.
The option of metastasectomy was reconsidered only after
a strong response to immunotherapy, which was often
associated with the resolution of multiple tumors.
Consistent with all series reporting metastasectomy for
patients with advanced melanoma, our study consisted of a
highly selected population. However, for patients who
achieved an objective response or had SD for at least 6
months, metastasectomy was used for 23 % of patients
with extracranial disease progression after ACT. The fact
that 9 of the 26 ACT patients achieved a PFS of over
24 months and 6 patients achieved a PFS of over
46 months after a single operation confirms that selected
patients relapsing after a response to immunotherapy can
safely undergo an effective salvage operation. Because
appropriate patient selection is both critical and difficult,
we also sought to identify clinical features that might
predict patients who were likely to benefit from surgical
resection. This study is an exploratory analysis of a small
cohort; consequently a Bonferroni correction was not per-
formed. The small numbers of patients put it at high risk
for type II error. Even still, the only variable significantly
associated with favorable PFS and OS after surgery was if
pre-existing sites of disease were resected versus new sites
that appeared after immunotherapy. Of note was the fact
that stable or still shrinking sites of disease were not
resected in some patients, yet PFS and OS that was similar
to patients who were made disease free. Our experience
suggests that stable or still responding sites of metastatic
melanoma may not need to be resected following a
response to ACT.
As previously noted, Gyorki et al. described the Memorial
Sloan Kettering Cancer Center experience with 23 patients
undergoing surgery for metastatic melanoma while receiv-
ing ipilimumab, and noted that 3 patients remained free of
disease and 10 were alive with disease. The report by Gyorki
et al., combined with our findings, prompted us to review our
experience with metastasectomy following treatment with
ipilimumab using the same criteria that were described in the
Methods section herein. We had previously reported our
experience with 177 patients treated with ipilimumab for
metastatic melanoma.10 From this group, 32 patients met our
response criteria and progressed at extracranial sites. Ulti-
mately, 6 of these 32 patients (19 %) underwent
metastasectomy as the next treatment, and 3 have remained
disease-free for over 5 years. Interestingly, these long-term
survivors were made NED with surgery and had resection of
pre-existing sites of disease.
CONCLUSIONS
Our experience suggests that long PFS can be achieved
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FIG. 3 Kaplan–Meier curves showing progression-free survival and overall survival of patients after resection of a pre-existing tumor (n = 19;
blue line) or a new tumor (n = 7; yellow line). Univariate analysis was performed using the log-rank test
140 N. D. Klemen et al.
melanoma following treatment with ACT. Approximately
23 % of patients with a CR, PR, or SD6 before subsequent
tumor progression were candidates for salvage metasta-
sectomy. Patients who had resection of pre-existing tumors
had favorable PFS and OS compared with patients under-
going resection of new disease sites. Due to the
retrospective and exploratory design of this study, these
findings will need to be evaluated by other institutions with
larger numbers of patients. Finally, it will be important to
determine if our experience with salvage metastasectomy
following ACT offers insights for the management of
patients with melanoma who develop tumor progression
following a response to checkpoint inhibitors.
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